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Small interfering RNA (siRNA) is currently being evaluated not only as a powerful tool for functional genomics, but also as a potentially
promising therapeutic agent for cancer and infectious diseases. Inhibitory effect of siRNA on viral replication has been demonstrated in
multiple pathogenic viruses. However, because of the high sequence specificity of siRNA-mediated RNA degradation, antiviral efficacy of
siRNA directed to viral genome will be largely limited by emergence of escape variants resistant to siRNA due to high mutation rates of
virus, especially RNAviruses such as poliovirus and hepatitis C virus (HCV). To investigate the therapeutic feasibility of siRNAs specific for
the putative cellular cofactors for HCV, we constructed adenovirus vectors expressing siRNAs against La, polypyrimidine tract-binding
protein (PTB), subunit gamma of human eukaryotic initiation factors 2B (eIF2Bg), and human VAMP-associated protein of 33 kDa (hVAP-
33). Adenoviral-mediated expression of siRNAs markedly diminished expression of the endogenous genes, and silencing of La, PTB, and
hVAP-33 by siRNAs substantially blocked HCV replication in Huh-7 cells. Thus, our studies demonstrate the feasibility and potential of
adenoviral-delivered siRNAs specific for cellular cofactors in combating HCV infection, which can be used either alone or in combination
with siRNA against viral genome to prevent the escape of mutant variants and provide additive or synergistic anti-HCV effects.
D 2004 Elsevier Inc. All rights reserved.Keywords: Small interfering RNA; Hepatitis C virus; Cellular factor; Antiviral agentsIntroduction
Hepatitis C virus (HCV) is the major causative agent of
non-A, non-B viral hepatitis (Choo et al., 1989), which
frequently leads to liver cirrhosis and hepatocellular carci-
noma (Saito et al., 1990). It has been estimated that more
than 3% of the world population is infected with HCV. The
only current medical therapy for HCV infection is IFN either
alone or in combination with ribavirin. Unfortunately, only a
small fraction of treated patients develop a sustained remis-
sion. Thus, development of new therapies for HCV infection
is of great clinical and economic significance.
RNA interference (RNAi) is an evolutionarily conserved
phenomenon of posttranscriptional gene silencing (PTGS)0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: j-zhang@fuso-pharm.co.jp (J. Zhang).that has been described in plants, invertebrates, and verte-
brates. In this process, double-stranded RNA (dsRNA) is
cleaved into small interfering RNAs (siRNAs) of 21–23 nt
by an RNaseIII-like enzyme known as Dicer, followed by
incorporation of siRNA into a RNA-induced silencing
complex (RISC) that recognizes and cleaves the target. In
mammals, however, it has been reported that long dsRNAs
(larger than 30 nt in length) induce an antiviral interferon
response and, in turn, lead to the nonspecific translational
shutdown. Thus, its application to mammalian cells is
largely limited. A crucial insight came from Elbashir et al.
(2001), who found that specific gene silencing in mamma-
lian cells can be mediated by siRNAs of 21 nt, which can
bypass dsRNA-induced nonspecific interferon response.
This significantly facilitated the use of siRNA technology
in mammalian cells. As a powerful reverse genetic ap-
proach, siRNA contributes greatly to linking of gene se-
quence with biological function. Additionally, the potential
of using siRNA for prevention and treatment of viral
infection has also proved to be promising. A couple of
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on respiratory syncytial virus (Bitko and Barik, 2001), HIV
(Jacque et al., 2002), poliovirus (Gitlin et al., 2002), and
more recently on HCV (Randall et al., 2003). Although
these studies have taken us to a fascinating new field in
antiviral therapy, one outstanding drawback of the approach
using siRNA direct against viral genome is that genetic
heterogeneity due to high mutation rates of viruses may lead
to emergence of escape variants resistant to siRNA. Indeed,
it was shown that a single point mutation in the siRNA
target region conferred escape in poliovirus (Gitlin et al.,
2002). Alternatively, cellular factors involved in the viral
life cycle provide more attractive candidates for siRNA
targeting to ensure a sustained antiviral effect. For example,
it has been reported that siRNAs targeted to the HIV-1 main
receptor, CD4 (Novina et al., 2002), or coreceptor, CCR5
(Qin et al., 2003), can suppress the entry and replication of
HIV-1.
In this study, we investigated the therapeutic feasibility of
siRNAs specific for the putative cellular cofactors for HCV,
including La, polypyrimidine tract-binding protein (PTB),
subunit gamma of human eukaryotic initiation factors 2B
(eIF2Bg), and human VAMP-associated protein of 33 kDa
(hVAP-33). Our results demonstrate that knockdown of the
endogenous La, PTB, or hVAP-33 with adenoviral-deliv-
ered siRNA efficiently inhibits HCV RNA replication in
cultured cells.Results
Silencing of the endogenous genes in Huh-7 cells
Although the exact significance is not fully understood,
there is increasing experimental evidence that showed
specific interaction between various cellular factors and
HCV RNA or viral protein, implicating potential roles of
these proteins in HCV RNA replication and/or translation.
Among these cellular factors, La antigen was shown to bind
to the 5V-untranslated region (UTR) of HCV (Ali and
Siddiqui, 1997), PTB was shown to interact with both 5V-
and 3V-UTR (Ali and Siddiqui, 1995; Tsuchihara et al.,
1997), and hVAP-33, a SNARE-like protein, was found to
specifically bind to NS5A and NS5B proteins, suggesting
that it may be responsible for the association of the HCV
replication complexes with the membrane (Tu et al., 1999).
Additionally, eIF2Bg was identified as a cofactor of HCV
cap-independent translation (Kruger et al., 2000). To ex-
plore whether these presumed HCV cofactors can be used as
functional targets for therapeutic siRNA, we first screened
the RNAi activity of several synthetic siRNA molecules for
each target gene (data not shown) and the most potent one
was further used to construct siRNA expression plasmids
(Fig. 1A). The small-hairpin RNAs are transcribed from
each of these plasmids under the control of human U6
promoter. Huh-7 cells were transfected with each siRNA-expressing plasmid, and the expression level of each en-
dogenous gene in the transfected cells was assessed by
Northern blot analysis. When compared with the empty
vector pShuttle, siRNA-expressing plasmid reduced the
mRNA level of their respective target genes, albeit with
different degree (Fig. 1B). The mRNA level of GAPDH,
which served as an internal control for RNA loading,
remained constant in each lane. Expectedly, each siRNA
had no effect on the expression level of the irrelevant genes,
confirming a specific RNAi effect induced by expressed
siRNA.
Effects of the endogenous gene silencing on HCV internal
ribosome entry site-dependent translation
Both La and PTB were shown to bind to HCV RNA in
5V-UTR, which constitutes internal ribosome entry site
(IRES), indicating their potential roles in regulating HCV
IRES-mediated translation. However, while Siddiqui and
co-workers reported that La antigen (Ali et al., 2000) and
PTB (Anwar et al., 2000) greatly enhance HCV IRES-
mediated translation, Kaminski et al. (1995) contradicted
the role of PTB in translation of HCV RNA, and Isoyama et
al. (1999) found low requirement of La protein for HCV
IRES activity. Translation is one of the processes in viral
replication, and authentic cofactors for HCV IRES function
are promising targets for therapeutic siRNA. To further
clarify the conflicting issue on the functional role of these
proteins in IRES-mediated translation, HepT cells stably
expressing T7 RNA polymerase (Zhang et al., 1999) were
transfected with each pShuttlesiRNA and the reporter vector
pNC371RL (Zhang et al., 2002), which contains a T7
promoter, nt 1–371 of HCV sequence fused in frame with
the Renilla luciferase (Rluc) gene. The cell lysates were
assayed for the HCV IRES-dependent Rluc expression 48
h following transfection. To analyze the influence of the
siRNA-mediated gene silencing on cap-dependent transla-
tion, pGL3-Control vector was cotransfected and the firefly
luciferase (Fluc) activity was measured simultaneously.
Compared with the Rluc activity in cells transfected with
the empty vector pShuttle (100%), the Rluc activities in
cells transfected with pShuttlesiLa, pShuttlesiPTB, pShut-
tlesieIF2B, and pShuttlesihVAP were 57.8%, 62.6%, 98.2%,
and 66.0%, respectively (Fig. 2A). While the cap-dependent
Fluc expression was comparable in these transfectants,
except a marginal reduction in cells transfected with pShut-
tlesieIF2B. To test the specificity of inhibition by siRNAs,
reporter assay with pEMCVRL, in which the translation of
Rluc gene is directed by encephalomyocarditis virus
(EMCV) IRES identical to that inserted in the HCV repli-
con, was also conducted as described above. As shown in
Fig. 2B, the EMCV IRES-directed Rluc expression was not
significantly affected by expression of siLa, siPTB, and
sieIF2B, whereas a moderate inhibition of EMCV IRES-
dependent translation was observed in cells expressing
sihVAP. These results provide further evidence of La and
Fig. 1. (A) Schematic diagram of the siRNA expression cassette. The short hairpin form of siRNA is expressed under the control of a human U6 promoter. The
five thymidines serve as a terminal signal. The sense and antisense siRNA strands are separated by a loop of 9 nt. Numbers indicate the positions of each target
cDNA sequence. (B) Reduction of endogenous gene expression in Huh-7 cells transiently transfected by siRNA-expressing plasmids. Huh-7 cells were
transfected with the indicated plasmids, and total RNAs were prepared at 48 h posttransfection. The mRNA level of La (upper left), PTB (upper right), eIF2Bg
(lower left), and hVAP-33 (lower right) was analyzed by Northern blot with each specific probe. GAPDH served as a loading control.
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quently suggests the utility of these host factors-targeting
siRNAs in combating HCV infection. Simultaneously, the
data presented here also suggest a functional relevance of
hVAP-33 in both HCV and EMCV IRES-controlled trans-
lation initiation, which has not been reported previously.
The mechanism underlying this observation and whether
hVAP-33 is a universal internal initiation factor are to be
further investigated.
Enhanced siRNA effect by adenoviral-mediated gene
delivery
One important issue in utilizing siRNAs as therapeutic
agents for human disease is how to deliver them to cells ofaction. Among the gene delivery vehicles currently used in
gene therapy approach, adenovirus is an attractive candi-
date for delivering siRNA against HCV, because it elicits
long-lived transgene expression and allows targeting to the
liver in vivo. Thus, we next cloned each siRNA expression
cassette into recombinant adenovirus vector. Huh-NNRZ
cells stably replicating the HCV subgenomic replicon were
transduced with each siRNA-expressing adenovirus at the
multiplicity of infection (MOI) of 80, 30, and 10, cells
were harvested at day 3 postinfection. Target mRNAs and
proteins were analyzed by Northern and Western blot
analysis in parallel. Transduction of the siRNA-expressing
adenoviruses dose-dependently reduced the expression of
their respective target genes, and the mRNAs or proteins
of endogenous genes were markedly diminished by infec-
Fig. 2. Effect of endogenous genes silencing on HCV (A) or EMCV (B)
IRES-dependent translation. HepT cells stably expressing T7 RNA
polymerase were transfected with the reporter vector pNC371RL (A) or
pEMCVRL (B), pGL3-Control vector, and the indicated siRNA-expressing
plasmid. The cap-dependent firefly (Fluc) (shaded columns) and the IRES-
dependent Renilla (Rluc) (dotted columns) luciferase activities in the
lysates were determined at 48 h posttransfection. The columns and bars
represent the means and standard deviations of three independent triplicate
transfections. *P < 0.05 compared with pShuttle.
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While infection with the irrelevant AdsiLuc expressing
siRNA against luciferase gene, even at the MOI of 80,
had no effect on the expression of the target genes. Thus,
adenovirally expressed siRNA elicits much more potentRNAi activity when comparing with transient transfection
of plasmids.
Effects of the endogenous gene silencing on HCV
replication
To test the therapeutic potential of these siRNAs, we next
investigate the effect of the endogenous gene silencing on
HCV replication. Because HCV does not grow in cultured
cells, we evaluated antiviral efficacy of the siRNAs in Huh-
7 cells harboring an autonomously replicating HCV sub-
genome (Huh-NNRZ cells) (Kishine et al., 2002). Structur-
ally, the subgenomic replicon in Huh-NNRZ cells contains
the 5V-UTR, the first 36 nucleotides of the core region fused
directly with the neomycin phosphotransferase gene, IRES
element from EMCV, a nonstructural protein (NS) region
from NS3 to NS5B and the 3V-UTR of HCV genome. The
G418 resistance of Huh-NNRZ cells is conferred by persis-
tent expression of neomycin phosphotransferase from rep-
licating HCV RNAs. Thus, the ability of Huh-NNRZ cells
to grow in G418-containing medium is an indirect measure
of HCV replication. Huh-NNRZ cells were infected with
AdsiLa, AdsiPTB, AdsieIF2B, AdsihVAP, or AdsiLuc at the
MOI of 80, 30, and 10, and cultured in the absence or
presence of G418 selection. After 10 days, the viable cells
that were resistant to G418 because of the propagation of
replicon were quantified with Cell Proliferation Reagent
WST-1. In the absence of G418, viability of the cells
transduced with each AdsiRNA was comparable to that of
mock-infected cells (Fig. 4), except a moderate decrease in
cells infected at the MOI of 80, probably reflecting some
cellular toxicity or impaired survival due to higher degree of
endogenous gene silencing. Following a 10-day exposure to
G418, cells transduced with AdsiLa, AdsiPTB, and Adsih-
VAP showed a substantial and dose-dependent reduction in
viable cell count, decreasing viable cell count by 99% and
97% at the MOI of 80 and 30, respectively. Significantly,
even a modest reduction of La and PTB expression by
infection of AdsiRNA at the MOI of 10 (Fig. 3) also
resulted in substantial inhibition of HCV replication, leading
to a 95% and 90% reduction in viable cell count, respec-
tively. These results indicated that G418 resistance in most
cells was lost due to the down-regulation of replicating
HCV RNA by siRNA-mediated endogenous gene silencing.
Consistent with the results from reporter assay, transduction
with AdsieIF2B (Fig. 4) or irrelevant AdsiLuc (data not
shown) had no significant effect on cell growth in the
presence of G418. Because synthesis of the nonstructural
proteins from the replicon is directed by EMCV IRES,
silencing of cellular cofactor for EMCV IRES may also
block the replication of HCV replicon. However, EMCV
IRES-mediated translation was not affected by siLa or
siPTB under the conditions in our study (Fig. 2B), so we
conclude that significant loss of G418 resistance in replicon
cell by depletion of La or PTB reflected a net interference
effect of siLa and siPTB on HCV infection. In addition to
Fig. 3. Dose-dependent silencing of endogenous genes in Huh-NNRZ cells transduced with siRNA expression adenoviral vectors. Huh-NNRZ cells harboring
HCV replicon were infected with each AdsiRNA at the MOI of 10, 30, and 80. The transduced cells were harvested at day 3 postinfection. The mRNA (A) and
protein level (B) of the cellular factors were analyzed by Northern and Western blot. GAPDH and actin were served as controls for RNA and protein loading,
respectively.
J. Zhang et al. / Virology 320 (2004) 135–143 139
Fig. 4. Influence of the endogenous genes silencing on HCV replication. Huh-NNRZ cells coated on 12-well plate were infected with each AdsiRNA at the
indicated MOI, and maintained either in the absence (shaded columns) or presence (dotted columns) of G418 selection. The viable cells were quantified after
10 days. Representative data are from three independent experiments.
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for siRNA action, especially in the case of siPTB, because
a specific interaction with 3V-UTR and a potential role in
HCV minus-strand synthesis were reported for PTB. On
the other hand, because both HCV and EMCV IRES-
directed translation were inhibited by siRNA-mediated
depletion of hVAP-33 (Fig. 2), the degree of antiviral
effect of sihVAP may be overestimated here. Nonetheless,
the results presented here demonstrate that siRNA-mediat-
ed silencing of the endogenous genes such as La, PTB,
and hVAP-33 can efficiently inhibit HCV replication in
cultured cells.Discussion
Recently, a couple of laboratories have demonstrated
RNAi-based inhibition of HIV, poliovirus, and HCV,suggesting a potentially promising application of siRNA
in antiviral therapy. However, it was shown that absolute
conservation of the base-pairing in the siRNA target
region is required for efficient cleavage, and if even a
single nucleotide differs between an siRNA and its target,
the effect is greatly diminished, or even eliminated
completely. Therefore, in attacking HCV RNA directly,
it is necessary to target viral RNA sequences that are
conserved and normally invariant among different strains.
Although the 5V-UTR and the 5V-end of core region are
relatively conserved, considerable genetic diversity exists
among various HCV isolates. The 5V-UTR region consti-
tutes the IRES capable of initiating cap-independent
translation of HCV. Highly ordered RNA structures and
multiple sites participating in RNA–protein interaction
within 5V-UTR have been documented to be critical for
promoting internal initiation and/or its control, both of
which might prevent recognition by siRNA. Thus, it may
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genome for therapeutic siRNA. Furthermore, because of
the inaccuracy of RNA-dependent RNA polymerase, mu-
tated progeny virus may rapidly emerge and escape from
recognition by siRNA.
Here, we investigated whether siRNAs directed to
cellular genes presumably essential for viral infection
can inhibit HCV replication in cultured cells. Our results
presented here showed that adenoviral-delivered siRNAs
elicited potent RNAi effect on endogenous genes, and
silencing of La, PTB, and hVAP-33 by AdsiRNA conse-
quently blocked HCV replication in Huh-7 cells. Signif-
icantly, even a modest reduction of La and PTB
expression by infection of AdsiRNA at the MOI of 10
also resulted in substantial inhibition of HCV replication,
decreasing viable (infected) cells by 20- and 10-fold,
respectively (Fig. 4). By demonstrating that the replication
of the preexisting HCV replicon can be efficiently sup-
pressed by cofactor-targeting siRNAs, it is conceivable
that pretreatment of naive liver cells with these siRNAs
could protect them from HCV infection. This would be
particularly useful in preventing newly transplanted livers
from reinfection with HCV.
Besides the attenuation of HCV IRES activity by siLa
and siPTB, the effective anti-HCV effect may partially be
attributed to the interference with HCV RNA replication.
This is especially true in the case of siPTB, because PTB
has been shown to bind to the 3V-end of the HCV RNA at
two conserved stem–loop structures, which is critical for
minus-strand synthesis (Tsuchihara et al., 1997; Ito and
Lai, 1997). The data presented here showed a function
relevance of hVAP-33 in HCV IRES-dependent transla-
tion, together with the previous study suggesting that
hVAP-33 may participate in HCV replication by serving
as a membrane receptor for replication complex (Tu et al.,
1999), implicating that hVAP-33 may be a cellular factor
playing a role in regulating the switch between translation
and replication of HCV RNA. If this is the case,
depletion of hVAP-33 by sihVAP may inhibit both
translation and replication of HCV RNA, the processes
which may be coupled, as that reported in poliovirus
(Novak and Kirkegaard, 1994).
Different from the genomic structure of native HCV in
which the viral polyprotein is translated under the control
of its IRES, synthesis of the nonstructural protein in the
replicon is initiated by EMCV IRES, whereas translation
of the neomycin phosphotransferase is directed by HCV
IRES. Theoretically, silencing of cellular factors, which
are specific for HCV IRES, does not affect the expression
level of nonstructural proteins, and consequently, replica-
tion of HCV replicon may not be altered. Accordingly,
quantification of HCV RNA transcripts or protein expres-
sion would underestimate the authentic anti-HCV effect of
the siRNAs against cofactors for HCV IRES. In view of
this respect, we assessed anti-HCV efficacy of the siRNAs
by measuring the loss of G418 resistance, which can betaken as a comprehensive measure of HCV infection
including both translation and RNA replication. Further
experiments with other HCV-permissive cell culture or
small animal models of chronic hepatitis C are required to
validate the anti-HCV function of these siRNAs. Addi-
tionally, it is important to confirm that silencing of these
endogenous genes by siRNA has no serious deleterious
effects. La protein is an autoimmune antigen that is
transiently associated with the 3V oligo (U) terminus of
the RNA polymerase III transcripts and facilitates tran-
scription termination and recycling of transcription com-
plexes for reinitiation process (Maraia, 1996). One
concern is whether La silencing may affect the transcrip-
tion of tRNAs, 5SrRNA, and other transcripts synthesized
by pol III. PTB is an RNA-binding protein recognizing
pyrimidine-rich sequence, playing a role in regulating
alternative splicing by selectively repressing 3V splice sites
(Singh et al., 1995). Also unknown is whether knock-
down of PTB may lead to perturbation of cellular RNA
processing. hVAP-33 has a typical SNARE structure,
potentially involved in diverse vesicle trafficking between
membrane compartments, although its precise functions
are unknown currently. One possibility is that partial
depletion of hVAP-33 may affect the vesicle transport
functions of cells. Further studies are required to deter-
mine whether this endogenous gene silencing is truly
limited by its roles in cells. Nonetheless, the results
presented here provide proof of principle for the idea
that siRNA directed to cellular cofactor can serve as a
potential therapeutic agent for HCV infection, which can
be used either alone or in combination with siRNA
directed to HCV RNA genome. It is theoretically possible
that siRNA simultaneously targeting cellular and viral
gene could help to prevent the escape of mutant variants
and provide additive or synergistic effects.
In addition to the therapeutic significance, the siRNA-
based approach allowed us to provide further evidence
for the functional requirement of La and PTB in the
HCV IRES-mediated translation, not only in the reporter
system, but also in the context of HCV replicon. In
contradiction to those reported by Kruger et al. (2000),
our data do not support a role of eIF2Bg in regulating
HCV IRES function. As shown in Fig. 4, the G418-
resistant phenotype of replicon cells, which is conferred
by HCV IRES-directed translation of neomycin phospho-
transferase, was not affected by transduction with
AdsieIF2B, although a significant silencing of endoge-
nous eIF2Bg was observed. These results substantially
lessen, if could not rule out completely, the possibility
that eIF2Bg is a cofactor for HCV IRES. The basis for
the discordance in the data presented by Kruger et al.
and those presented here is currently unknown. Unex-
pectedly, our data showed a biological relevance of
hVAP-33 in both HCV and EMCV IRES-mediated trans-
lation. To our knowledge, involvement of hVAP-33 in
IRES-dependent translation has not been reported previ-
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factor that is indispensable in every case of internal
initiation is to be further investigated.
In conclusion, the results presented here demonstrate that
adenoviral-delivered siRNA specific to cellular genes such
as La, PTB, and hVAP-33 significantly inhibit viral repli-
cation in cultured Huh-7 cells. These data also suggest that
siRNA-based approach is a powerful tool for identification
of novel HCV cellular cofactors yet to be described, thereby
facilitating the development of new antiviral therapy for
HCV infection.Materials and methods
Plasmids
The U6 pol III promoter was amplified by PCR from
the genomic DNA of the HeLa cells with a sense primer
containing a MfeI site 5V-atgcaattgAAGGTCGGGCAG-
GAAGA-3V and an antisense primer containing an EcoRI
and a BamHI site 5V-agaattcggatccCGCGTCCTTTCCA-
CAAGATA-3V. The PCR product was digested with MfeI
and EcoRI, and cloned into the MfeI and EcoRI sites of
pShuttle (Clontech) to create pShuttleU6. Target sequen-
ces for siRNAs were selected according to the Ambion
web-based criteria and further analyzed by BLAST re-
search to avoid a significant homology with other genes.
For each endogenous gene (La, PTB, eIF2Bg, or hVAP-
33), sense and antisense oligonucleotides of self-comple-
mentary hairpin sequences (including the termination
signal of five thymidines), which contain cohesive ends
for BamHI and EcoRI at the 5V- and 3V-ends, were
synthesized and annealed by heating at 95jC for 10
min and slowly cooled down to room temperature. After
a gel electrophoresis purification, these annealed oligonu-
cleotides were inserted into the BamHI and EcoRI sites of
pShuttleU6. The resultant vectors are termed pShuttlesiLa,
pShuttlesiPTB, pShuttlesieIF2B, and pShuttlesihVAP, re-
spectively. The sequences of these constructs were con-
firmed by nucleotide sequencing.
Adenovirus
Each siRNA-expressing cassette in pShuttlesiRNA,
which is flanked by I-CeuI and PI-SceI sites, was digested
with these two enzymes, and ligated to the E1- and E3-
deleted Adeno-X Viral DNA (I-CeuI and PI-SceI
digested) (Adeno-X Expression System, Clontech). The
resultant adenoviral DNAs were digested with PacI and
then transfected into low-passage 293 cells. Seven days
following transfection, crude virus was prepared from the
transfected cells by three cycles of freeze–thawing, and
further amplified in 293 cells by several rounds of
infection. The purified virus was aliquoted and stored at
80jC before use. The authenticity of all recombinantadenoviral DNAs was verified before preparing high-titer
viral stocks.
Cells
The cell lines Huh-7 and 293 were purchased from the
American Type Culture Collection (ATCC) and maintained
in Dulbecco’s modified Eagle’s medium (DMEM, Invitro-
gen) supplemented with 10% fetal calf serum and 50 units/
ml penicillin and streptomycin in a 5% CO2 humidified
atmosphere. The cell line HepT, which stably expresses T7
RNA polymerase (Zhang et al., 1999), was grown in
DMEM containing 5 Ag/ml puromycin (Sigma). A Huh-7-
derived cell line (Huh-NNRZ) stably replicating HCV sub-
genomic replicon (referred to as #50-1 cell clone in Kishine
et al., 2002) was grown in DMEM containing 300 Ag/ml
G418 (Geneticin, Invitrogen).
Northern and Western blot analysis
Total RNAs were isolated from culture cells with
Trizol reagent (Invitrogen), separated by denaturing aga-
rose gel electrophoresis, and analyzed by Northern blot
using Dig-labeled probes. The probes correspond to
nucleotides 72–581 of the cDNA for La, 88–656 for
PTB, 87–598 for eIF2Bg, and 16–506 for hVAP-33.
Western blot analysis was performed on total lysates from
mock- or AdsiRNA-infected Huh-NNRZ cells. Protein
was electrophoresed on a sodium dodecyl sulfate-poly-
acrylamide gel, transferred to Immobilon PVDF Transfer
Membrane (Millipore). The blots were probed with mono-
clonal antibodies specific for La (clone La4B6, Progen
Biotechnik GmbH), PTB (clone 1, Zymed Laboratories,
Inc.), and eIF2Bg (sc-9980, Santa Cruz Biotechnology,
Inc.). Proteins were visualized by using Immun-Blot
Assay Kit (Bio-Rad).
Transfection
HepT cells were seeded onto 35-mm-diameter tissue
culture dishes 24 h before transfection. Four micrograms of
each pShuttlesiRNA, 2 Ag of the reporter vector, pNC371RL
or pEMCVRL, and 0.2 Ag of pGL3-Control vector were
cotransfected into HepT cells with TransFast Transfection
Reagent (Promega). The cells were harvested after 48 h, and
cell lysates were assayed for luciferase activity as described
below.
Luciferase assay
Cell lysates were prepared from transfected cells, centri-
fuged briefly, and 20 Al of the supernatants was used for
luciferase assays with Dual-Luciferase Reporter Assay Sys-
tem (Promega) according to the manufacturer’s instructions.
Luciferase activities were measured using a TD-20/20
Luminometer (Promega).
logy 320 (2004) 135–143 143Quantification of cell viability
Cell viability was measured with Cell Proliferation
Reagent WST-1 (Roche) according to the manufacturer’s
instructions.
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